Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60.4% | -4.2% | 177.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 50.6% | 102.5% | 83% | 58.3% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 9.4% | 54.7% | 69.2% | 11.5% |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | -3.9% | 43.8% | 55.8% | -13.1% |
| EPS Diluted | -0.13 | 3.43 | 4.71 | -0.4 |
| % Growth | -103.8% | -27.2% | 1,277.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | $0 | $0 |